The Assessment of SpondyloArthritis International Society (ASAS) Consensus-Based Expert Definition of Difficult-to-Manage, including Treatment-Refractory, Axial Spondyloarthritis (2025)
https://pubmed.ncbi.nlm.nih.gov/39955166/

Minimal tofacitinib dose for maintenance in axial spondyloarthritis: real-world data from a resource-limited setting (2025)
https://pubmed.ncbi.nlm.nih.gov/40026266/

Social Media Use Among Members of the Assessment of Spondyloarthritis International Society: Results of a Web-Based Survey (2023)
https://pubmed.ncbi.nlm.nih.gov/36626201/

Management of Peripheral Arthritis in Patients With Psoriatic Arthritis: An Updated Literature Review Informing the 2021 GRAPPA Treatment Recommendations (2023)
https://pubmed.ncbi.nlm.nih.gov/36243409/

Evaluation of the predictive validity of the ASAS axial spondyloarthritis criteria in the DESIR cohort (2019)
https://pubmed.ncbi.nlm.nih.gov/30873948/

Evaluation of extreme patient-reported outcome in early spondyloarthritis and its impact on the effect of TNF-α blockers treatment (2018)
https://pubmed.ncbi.nlm.nih.gov/30183594/

An Assessment in SpondyloArthritis International Society (ASAS)-endorsed definition of clinically important worsening in axial spondyloarthritis based on ASDAS (2018)
https://pubmed.ncbi.nlm.nih.gov/29038299/